Welcome to our dedicated page for Sanuwave Health SEC filings (Ticker: SNWV), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Sanuwave Health, Inc. (SNWV) SEC filings page on Stock Titan provides access to the company’s U.S. Securities and Exchange Commission disclosures, including current reports on Form 8-K, proxy statements, and other regulatory documents. Sanuwave is a Nevada corporation whose common stock trades on NASDAQ under the symbol SNWV, and its filings offer detailed information on operations, governance, and financing.
Recent Forms 8-K describe results of operations and financial condition for specific quarters, including press releases announcing revenue, gross margin, operating income, and non-GAAP metrics such as EBITDA and Adjusted EBITDA. Other 8-K filings cover material definitive agreements, such as a secured credit facility with JPMorgan Chase Bank, N.A. that includes a term loan and revolving credit facility, and the termination of a prior debt facility with NH Expansion Credit Fund Holdings LP.
Additional 8-K items document corporate actions and governance events, including changes in executive officers, separation and release agreements, stockholder meeting results, and amendments to the 2024 Equity Incentive Plan. One filing also describes a license and option agreement related to intravascular shockwave patents and the subsequent exercise of the option by the licensee, resulting in a cash payment to Sanuwave.
Investors interested in capital structure and shareholder matters can review the company’s definitive proxy statement (DEF 14A), which discusses director elections, ratification of the independent registered public accounting firm, advisory votes on executive compensation, and details of the reverse stock split of Sanuwave’s common stock.
On Stock Titan, these filings are updated from the SEC’s EDGAR system, and AI-powered tools can help summarize key points, highlight significant items in Forms 8-K, and clarify the implications of proxy proposals and financing agreements. This allows readers to quickly understand how Sanuwave’s regulatory disclosures relate to its advanced wound care and regenerative medicine business.
SANUWAVE Health executive receives stock option grant
SANUWAVE Health, Inc. granted Exec VP of Sales David Timothy Wern a stock option for 2,500 shares of common stock on January 30, 2026. The option has an exercise price of $26.96 per share and expires on January 30, 2036.
The filing shows the full 2,500 options are held directly after the transaction. According to the footnote, these options will vest over three years in 12 equal quarterly installments starting from the grant date, tying the award to ongoing service and performance over time.
SANUWAVE Health reported that Chief Executive Officer and director Morgan C. Frank received a new stock option grant. On 01/30/2026, he was awarded options to purchase 24,000 shares of common stock at an exercise price of $26.96 per share, expiring on 01/30/2031.
The options were granted at no cost on the grant date and will vest in four equal installments on the last day of each quarter during 2026, aligning vesting with the company’s quarterly performance periods.
Sanuwave Health, Inc. filed an amended report to update the outcome of its advisory vote on how often shareholders will be asked to approve executive compensation. After the 2025 annual meeting, where shareholders favored a one-year cycle, the Board decided on annual say-on-pay votes.
The Board resolved on January 7, 2026 to hold these advisory votes every year until the next required vote on frequency, which will occur no later than the company’s 2031 annual meeting of stockholders. No other items from the prior report were changed.
SANUWAVE Health Chief Executive Officer Morgan C. Frank, who also serves as a director, reported receiving a new stock option award. On 12/31/2025, he was granted a stock option to buy 1,540 shares of common stock at an exercise price of $29.84 per share. The filing states that these options were fully vested at the grant date, meaning they are immediately exercisable, and they carry an expiration date of 12/31/2030. After this grant, Frank beneficially owns 1,540 derivative securities in the form of these stock options, held directly.
SANUWAVE Health, Inc. director Tyler James reported receiving a stock option grant. On December 31, 2025, he was awarded 1,540 stock options giving the right to buy common stock at an exercise price of $29.84 per share. These options are shown as fully vested at the grant date and expire on December 31, 2030. After this grant, James beneficially owned 1,540 derivative securities, all held directly.
SANUWAVE Health, Inc. reported an insider equity award for director Jeffrey Blizard. On 12/31/2025, he received a stock option to purchase 1,540 shares of common stock at an exercise price of $29.84 per share, expiring on 12/31/2030.
The option was fully vested on the grant date, meaning it was immediately exercisable. Following this award, Blizard beneficially owns 1,540 derivative securities related to the company’s common stock, held as a direct ownership position.
SANUWAVE Health affiliated holders reported sales of the company’s common stock by a group including JEB Partners, L.P. and related investment entities. On December 11, 2025, they sold 13,500 shares at a weighted average price of $31.2798, followed by a sale of 6,500 shares on December 12, 2025 at a weighted average price of $21.0444, both reported with transaction code “S.”
Following these transactions, 63,999 shares of SANUWAVE Health common stock were reported as indirectly beneficially owned through JEB Partners, L.P., with indirect interests attributed to Manchester Management Company, LLC, Manchester Management PR, LLC and James E. Besser. Additional lines report 2,000 shares directly owned by James E. Besser, 863,980 shares owned directly by Manchester Explorer, L.P., and 52,653 securities and warrants directly owned by Morgan C. Frank, with each party disclaiming beneficial ownership beyond their pecuniary interest.
Sanuwave Health (SNWV) furnished an 8-K announcing it issued a press release with financial results for the third quarter ended September 30, 2025.
The company also scheduled a business update conference call for November 7, 2025 at 8:30 a.m. EST. The press release is included as Exhibit 99.1, with materials available on the investor relations website. The information under Item 2.02 is being furnished, not filed.
SANUWAVE Health (SNWV) reported Q3 2025 results with revenue of
Year to date, revenue was
Balance sheet and liquidity: SANUWAVE closed a new credit agreement with a
SANUWAVE Health (SNWV) reported a leadership change and severance terms. Former President Andrew Walko was terminated without cause effective October 24, 2025, and entered a Separation and Release Agreement. The agreement provides $76,666.67 in cash, payable in equal installments over a four-month severance period, with an initial payment of one week’s base salary on October 31, 2025. Walko’s employee stock options will continue to vest during the severance period and remain exercisable until their stated expiration dates. The agreement includes a release of claims, confidentiality, and non-disparagement provisions.